Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer ...

Its products primarily comprise FlowTriever and ClotTriever systems, which are used to treat venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE). The company also ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

A mom who takes nothing for granted is sharing her story after almost dying from a pulmonary embolism during childbirth.

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the ...

Smart Investor: Why the Bond Selloff May Be Good News, Will the Fed Still Cut Rates, and What’s Next for the AI Trade. We wrap up our coverage of the markets and the week. We sell different ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The seemingly ordinary news of wedding plans for a young man whom she knew as a child reminds this doctor of how far medicine has come in treating cystic fibrosis — it only took a village.